

Funding for translational research to predict, prevent, and/or reduce unintended adverse effects from cancer therapy.

HESI THRIVE – Making Cancer Patient Quality of Life an Active Research Priority
Deadline Extended! - Letters of Intent Due July 1, 2019

THRIVE, a partner in the 2018 [Biden Cancer Initiative](#), provides **seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment**. THRIVE also supports the development of approaches to avoid or lessen these effects.

ELIGIBILITY

- PI's must hold an MD, PhD, DVM or equivalent degree. Candidates for these degrees along with their PI may apply.
- Candidates must have the ability to conduct independent research and have published in peer-reviewed journals.

FUNDING

- Range of \$20,000 - \$50,000 for up to 24 months
- Upon agreement to THRIVE award terms, THRIVE will disburse 75% of funds with the remaining provided upon completion of the study milestones.

APPLICATION PROCESS

- Thrive requires a letter of intent (LOI) in advance of the grant application. Only investigators who have submitted an LOI and been invited to submit a formal grant application will be considered for funding.
- LOI's are due **July 1, 2019**

SELECTION PROCESS

- The proposed study's scientific merit, innovation and ability to translate preclinical to clinical research (or vice versa) is key to being selected for funding.
- Preference given to studies in which both a non-clinical and a clinical researcher are engaged in either the design, conduct, or analysis or the study results (see attached guidelines for details).
- A total of 4-6 grants will be awarded in 2019.

THRIVE is interested in research that will advance our:

- Fundamental understanding of cancer drug or therapy-related toxicity;
- Ability to identify and translate critical biomarkers of toxicity;
- Models (in vitro, in vivo, in silico) of pediatric or adult drug exposure that predict early or impending toxicities;
- Understanding the role of protective co-therapies or modified exposure protocols on the onset of therapy-induced damage; and

- Identification of novel protective therapies or dosing strategies.

KEY DATES

LOI Submission Date – July 1, 2019

Notifications to be sent to submit full proposal – August 1, 2019

Full Proposals for selected LOIs due – September 16, 2019

Awards Selection and Notification - November 16 2019

Award Period Initiates – January 1 2020

For more information contact research@hesithrive.org